Compare Incyte Corporation (INCY) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Gartner Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Gartner Inc trades at $187.99 (market cap $11.83B). The key difference: Incyte Corporation is far larger — about 2.1× Gartner Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| INCY | IT | |
|---|---|---|
Market Cap | $24.54B | $11.83B |
Sector | Health | Technology |
52-Week High | $129.93 | $264.09 |
52-Week Low | $81.61 | $125.68 |
Enterprise Value | $20.04B | $13.57B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
